Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Costabel

Showing results (111-120 of 200) with videos related to

Pageof 20
Sort By:
Pneumologie (Stuttgart, Germany)|July 6, 2017
[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]Jürgen Behr, Andreas Günther, Francesco Bonella, et al.
Pneumologie (Stuttgart, Germany)|January 18, 2018
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017Jürgen Behr, Andreas Günther, Francesco Bonella, et al.
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
American Journal of Respiratory and Critical Care Medicine|March 17, 2009
Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndromeStephan Urs Sixt, Michael Adamzik, Daniel Spyrka, et al.
Respiratory Research|March 15, 2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Marilyn K Glassberg, et al.
Pneumologie (Stuttgart, Germany)|September 14, 2021
A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial PneumoniaDetlef Kirsten, Ulrike de Vries, Ulrich Costabel, et al.
Respiratory Medicine|February 1, 2017
FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosisChihiro Hirano, Shinichiro Ohshimo, Yasushi Horimasu, et al.
Respiration; International Review of Thoracic Diseases|April 12, 2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received PirfenidoneMichael Kreuter, Paolo Spagnolo, Wim Wuyts, et al.
The Lancet. Respiratory Medicine|September 19, 2018
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ONBruno Crestani, John T Huggins, Mitchell Kaye, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 4, 2014
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Williamson Z Bradford, et al.
Pageof 20

Showing results (111-120 of 200) with videos related to

Sort By:
Pageof 20
Pneumologie (Stuttgart, Germany)|July 6, 2017
[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]Jürgen Behr, Andreas Günther, Francesco Bonella, et al.
Pneumologie (Stuttgart, Germany)|January 18, 2018
German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017Jürgen Behr, Andreas Günther, Francesco Bonella, et al.
Respiration; International Review of Thoracic Diseases|February 8, 2018
Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary FibrosisMichael Kreuter, Ulrich Costabel, Luca Richeldi, et al.
American Journal of Respiratory and Critical Care Medicine|March 17, 2009
Alveolar extracellular 20S proteasome in patients with acute respiratory distress syndromeStephan Urs Sixt, Michael Adamzik, Daniel Spyrka, et al.
Respiratory Research|March 15, 2019
Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Marilyn K Glassberg, et al.
Pneumologie (Stuttgart, Germany)|September 14, 2021
A New Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis or Non-specific Interstitial PneumoniaDetlef Kirsten, Ulrike de Vries, Ulrich Costabel, et al.
Respiratory Medicine|February 1, 2017
FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosisChihiro Hirano, Shinichiro Ohshimo, Yasushi Horimasu, et al.
Respiration; International Review of Thoracic Diseases|April 12, 2017
Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received PirfenidoneMichael Kreuter, Paolo Spagnolo, Wim Wuyts, et al.
The Lancet. Respiratory Medicine|September 19, 2018
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ONBruno Crestani, John T Huggins, Mitchell Kaye, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|November 4, 2014
Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosisUlrich Costabel, Carlo Albera, Williamson Z Bradford, et al.
Pageof 20